Skip to main content

Table 1 qRT-PCR analysis of Wnt ligands and FZD receptor expression in primary MCL cells compared to B-cells from healthy donors

From: Targeting Wnt pathway in mantle cell lymphoma-initiating cells

 

MCL-non-ICs

MCL-ICs

P value

Median

95 % CI

Median

95 % CI

Wnt Ligands

 

 Up-regulated in MCL-non-ICs and MCL-ICs

 

  Wnt3a

17.555

0.12–56.05

34.52

2.49–91.86

0.0877

  Wnt11

3.66

0.19–8.91

32.61

0.84–69.97

0.1588

 Up-regulated in MCL-ICs

 

  Wnt5a

1.78

0.76–21.93

10.5

3.56–17.87

0.3465

  Wnt3

1.49

0.98–35.36

23.32

4.26–47.61

0.0500

  Wnt8b

1.25

0.39–2.60

3.89

1.45–15.16

0.2308

  Wnt4

1.76

0.21–6.13

3.41

0.54–5.65

0.2820

  Wnt7a

1.21

0.75–5.32

2.09

0.60–6.76

0.2715

  Wnt6

1.02

0.05–17.65

1.85

0.08–8.71

0.5133

  Wnt5b

0.66

0.42–18.82

45.47

0.95–146.30

0.1956

  Wnt1

0.45

0.15–12.25

9.26

4.18–15.20

0.1528

  Wnt7b

0.28

0.25–2.24

4.15

2.13–7.85

0.0156

  Wnt9b

0.39

0.15–1.47

2.44

1.08–8.79

0.1764

  Wnt2b

0.28

0.16–8.18

1.39

0.05–9.60

0.0802

  Wnt10a

0.67

0.24–14.80

0.96

0.03–4.41

0.5622

 Up-regulated in MCL-non-ICs

 

  Wnt9a

229.93

4.51–962.28

18.31

10.81–304.06

0.3201

  Wnt16

11.99

1.32–32.97

4.61

3.23–9.86

0.3029

  Wnt8a

6.97

0.24–18.73

1.01

0.15–2.32

0.1785

FZD Receptors

     

 Up-regulated in MCL-non-ICs and MCL-ICs

 

  Fz2

37.31

4.24–58.26

46.96

10.01–157.60

0.2909

  Fz7

4.53

0.49–9.76

4.48

1.89–9.04

0.9536

 Up-regulated in MCL-ICs

 

  Fz4

1.15

0.07–2.52

122.7

1.93–1340

0.3002

  Fz1

1.8

1.10–7.76

25.41

4.65–37.39

0.0390

  Fz5

1.43

0.99–4.45

7.37

3.58–8.77

0.0100

  Fz9

1.44

0.59–2.75

4.74

2.81–8.08

0.0379

  Fz10

0.64

0.29–1.44

4.26

3.91–10.99

0.0738

  Fz8

0.13

0.01–0.39

0.77

0.10–4.76

0.2907

 Up-regulated in MCL-non-ICs

 

  Fz6

5.02

4.47–5.59

1.34

0.66–1.85

0.0001

  Fz3

0.3

0.12–7.04

0.26

0.24–1.22

0.4814

  1. B-cells (median = 1) are used as reference. Median with 95 % confidence interval limits depicts the variations observed among patient samples. Differences between MCL-ICs and MCL-non-ICs were considered as significant with P < 0.05.
  2. MCL mantle cell lymphoma, ICs initiating cells